<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">sechenov</journal-id><journal-title-group><journal-title xml:lang="en">Sechenov Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Сеченовский вестник</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2218-7332</issn><issn pub-type="epub">2658-3348</issn><publisher><publisher-name>Сеченовский Университет</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">sechenov-573</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>УСПЕХИ КЛИНИЧЕСКОЙ МЕДИЦИНЫ</subject></subj-group></article-categories><title-group><article-title>Severe rheumatoid arthritis with multiple baseline anti-inflammatory drugs intolerance</article-title><trans-title-group xml:lang="ru"><trans-title>Тяжелое течение ревматоидного артрита с множественной непереносимостью базисных противовоспалительных препаратов</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кусевич</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kusevich</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кусевич Дарья Александровна, аспирант кафедры ревматологии</p><p>115522, г. Москва, Каширское шоссе, д. 34А </p></bio><bio xml:lang="en"><p>Darya A. Kusevich, Postgraduate Student at the Department of Rheumatology</p><p>34A, Kashirskoe shosse, Moscow, 115522</p></bio><email xlink:type="simple">kusevich@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Имаметдинова</surname><given-names>Г. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Imametdinova</surname><given-names>G. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, доцент кафедры ревматологии Института профессионального образования</p><p>Москва</p></bio><bio xml:lang="en"><p>Candidate of Medical Sciences, Assistant Professor with the Department of Rheumatology</p><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чичасова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chichasova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор кафедры ревматологии Института профессионального образования</p><p>Москва</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, Professor with Department of Rheumatology</p><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, академик РАН, профессор кафедры ревматологии Института профессионального образования</p><p>Москва</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, academician of Russian Academy of Sciences, Professor, Head of the Department of Rheumatology</p><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Первый МГМУ имени И.М. Сеченова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First MSMU</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2016</year></pub-date><volume>0</volume><issue>4</issue><fpage>53</fpage><lpage>57</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kusevich D.A., Imametdinova G.R., Chichasova N.V., Nasonov E.L., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Кусевич Д.А., Имаметдинова Г.Р., Чичасова Н.В., Насонов Е.Л.</copyright-holder><copyright-holder xml:lang="en">Kusevich D.A., Imametdinova G.R., Chichasova N.V., Nasonov E.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sechenovmedj.com/jour/article/view/573">https://www.sechenovmedj.com/jour/article/view/573</self-uri><abstract><p>The present study considers a care of a 42-year old female patient with a severe variant of rheumatoid arthritis and extra-articular manifestations. The debut clinical symptoms included polyarthritis, fever, and anemia. On selection of a basic therapy, intolerance (leucopenia, flu-like syndrome) and inefficiency of treatment regimen have been revealed. Administration of a genetically engineered biological drug resulted in the development of tuberculosis and the patient required a long break in the biotherapy for a specific treatment course. The use of anti-TNF agents is associated with an increased risk to tuberculosis and anti-TNF agents are stopped when active tuberculosis develops. However, discontinuation of treatment results in a flare of the underlying disease. The rituximab therapy was initiated because the clinicolaboratory activity was high. Due to the strategy “Treat to Target”, the patient reached improvement by classification criteria and clinical and laboratory remission. The use of high doses of glucocorticoids during the patient’s planning pregnancy led to the development of secondary osteoporosis with spontaneous fractures of pelvic bones and ribs, expressed progression of erosive process, deformations of small and large joints. Specific features of the course of disease with formation of a severe progressing form of rheumatoid arthritis and the conducted treatment were considered from the point of view of difficulty in the selection of therapy when rheumatologists had a limited arsenal of drugs. The risk of re-onset of tuberculosis infection mandates careful follow-up.</p></abstract><trans-abstract xml:lang="ru"><p>В настоящем исследовании рассматривается случай 42-летней пациентки с тяжелым вариантом ревматоидного артрита с системными проявлениями. У пациентки наблюдалось развитие туберкулезной инфекции на фоне приема генно-инженерного биологического препарата. Среди клинических симптомов в дебюте преобладали полиартрит, лихорадка, анемия. При попытке подбора базисной терапии выявлялась непереносимость (лейкопения, гриппоподобный синдром) и неэффективность схем терапии. Попытка назначения биологической терапии привела к развитию туберкулеза, длительному перерыву на курс специфического лечения. Учитывая сохраняющуюся высокую клинико-лабораторную активность, непереносимость и неэффективность предшествующей терапии и развитие туберкулезной инфекции на фоне приема препаратов группы ингибиторов фактора некроза опухоли альфа, была инициирована анти-B-клеточная терапия ритуксимабом, препаратом с другим механизмом действия, с выраженным положительным эффектом. У больной достигнуто улучшение по классификационным критериям, а затем и клинико-лабораторная ремиссия, благодаря следованию стратегии «лечение до достижения цели». Применение высоких доз глюкокортикоидов в период планирования пациенткой беременности привело к развитию вторичного остеопороза со спонтанными переломами костей таза и ребер, выраженной прогрессии эрозивного процесса, к деформациям мелких и крупных суставов. Особенности течения заболевания с формированием тяжелой неуклонно прогрессирующей формы ревматоидного артрита и проводимого лечения были рассмотрены с точки зрения трудности подбора терапии в период ограниченного арсенала лекарственных препаратов у врачей-ревматологов и до формирования концепции «лечение до достижения цели». Риск повторного развития туберкулезной инфекции сохраняется и требует тщательного мониторинга.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Ревматоидный артрит</kwd><kwd>генно-инженерные биологические препараты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Rheumatoid arthritis</kwd><kwd>genetic engineering biological agents</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Quinn M.A., Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin. Exp. Rheumatol. 2003; 21; Suppl 31: 154–157.</mixed-citation><mixed-citation xml:lang="en">Quinn M.A., Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin. Exp. Rheumatol. 2003; 21; Suppl 31: 154–157.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Чичасова Н.В., Владимиров С.А., Имаметдинова Г.Р., Иголкина Е.В., Насонов Е.Л. Функциональные исходы ревматоидного артрита при различных способах противовоспалительной терапии. Научно-практическая ревматология. 2010; 48(2): 30–36. DOI: 10.14412/1995-4484-2010-1413.</mixed-citation><mixed-citation xml:lang="en">Chichasova N.V., Vladimirov S.A., Imametdinova G.R., Igolkina E.V., Nasonov E.L. Functional outcomes of rheumatoid arthritis during various procedures of anti-inflammatory therapy. Rheumatology Science and Practice. 2010; 48(2): 30–36. DOI: 10.14412/1995-4484-2010-1413 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Goecor-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST study): a randomised, controlled trial. Arthr. Rheum. 2005; 52: 3381–3390.</mixed-citation><mixed-citation xml:lang="en">Goecor-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST study): a randomised, controlled trial. Arthr. Rheum. 2005; 52: 3381–3390.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">НасоновЕ.Л., МазуровВ.И., КаратеевД.Е., Лукина Г.В., Жиляев Е.В., Амирджанова В.Н., Муравьев Ю.В., Чичасова Н.В. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2015; 53(5s): 1–17. DOI: 10.14412/1995-4484-2015-1-17.</mixed-citation><mixed-citation xml:lang="en">Nasonov E.L., Mazurov V.I., Karateev D.E., Lukina G.V., Zhilyaev E.V., Amirdzhanova V.N., Muraviyov Y.V., Tchichasova N.V. Project: Recommendations on Treatment of Rheumatoid Arthritis Developed by All-Russian Public Organization «Association of Rheumatologists of Russia» – 2014 (Part 1). Rheumatology Science and Practice. 2015; 53(5s): 1–17. DOI: 10.14412/1995-4484-2015-1-17 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е.Л. (ред.). Генно-инженерные биологические препараты в лечении ревматоидного артрита. М.: ИМА-ПРЕСС; 2013: 552.</mixed-citation><mixed-citation xml:lang="en">Nasonov E.L. (ed.). Genetically engineered biological agents in the treatment of rheumatoid arthritis. Moscow: IMA-PRESS; 2013: 552 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Furst D.E., Keystone E.C., Braun J. et al. Update consensus statement on biological agents for the treatment of rheumatic disease, 2011. Ann. Rheum. Dis. 2012; 71 (Suppl II): i2-i45; Smolen J., Van der Heijde D.M., StClair E.W. et al. Prediction of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from ASPIRE trial. Arthr. Rheum. 2006; 54: 702–710.</mixed-citation><mixed-citation xml:lang="en">Furst D.E., Keystone E.C., Braun J. et al. Update consensus statement on biological agents for the treatment of rheumatic disease, 2011. Ann. Rheum. Dis. 2012; 71 (Suppl II): i2-i45; Smolen J., Van der Heijde D.M., StClair E.W. et al. Prediction of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from ASPIRE trial. Arthr. Rheum. 2006; 54: 702–710.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Solovic I., Sester M., Gomez-Reino J. et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement II. Eur. Respir. J. 2010; 36: 1185–1206.</mixed-citation><mixed-citation xml:lang="en">Solovic I., Sester M., Gomez-Reino J. et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement II. Eur. Respir. J. 2010; 36: 1185–1206.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dixon W.G., Symmons P.M., Lunt M. et al. Serious infection following anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Lessons from interpreting data from observational studies. Arthr. Rheum. 2007; 56: 2904–2986.</mixed-citation><mixed-citation xml:lang="en">Dixon W.G., Symmons P.M., Lunt M. et al. Serious infection following anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Lessons from interpreting data from observational studies. Arthr. Rheum. 2007; 56: 2904–2986.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Борисов С.Е., Лукина Г.В. Рекомендации по скринингу и мониторингу туберкулезной инфекции у больных, получающих генно-инженерные биологические препараты. 2013. Режим доступа: http://www.rheumatolog.ru/files/natrec21/.pdf (дата обращения: 05.12.2016).</mixed-citation><mixed-citation xml:lang="en">Recommendations about screening and monitoring of a tubercular infection at the patients receiving genetically engineered biological preparations. 2013. Available at: http://www.rheumatolog.ru/files/natrec21/.pdf (accessed December 5, 2016) (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Белов Б.С. Терапия генно-инженерными биологическими препаратами и инфекции у больных ревматоидным артритом: актуальность и перспективы. Научнопрактическая ревматология. 2014; 52(3): 322–330. DOI: http://dx.doi.org/10.14412/1995-4484-2014-322-330</mixed-citation><mixed-citation xml:lang="en">Belov B.S. Biological therapy and infections in patients with rheumatoid arthritis: relevance and prospects. Rheumatology Science and Practice. 2014; 52(3): 322–330. DOI: http://dx.doi.org/10.14412/1995-4484-2014-322-330 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е.Л. (ред.). Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Моногр. М.: ИМАПРЕСС; 2012: 344.</mixed-citation><mixed-citation xml:lang="en">Nasonov E.L. (ed.). Anti-B-cell therapy. Focus on rituximab. Moscow: IMA-PRESS; 2012: 344 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Сатыбалдыев А.М., Каратеев Д.Е. Международный опыт регистров больных ревматоидным артритом. Зарубежные регистры. Современная ревматология. 2014; 8(1): 83–84. DOI: 10.14412/1996-7012-2014-1-83-84.</mixed-citation><mixed-citation xml:lang="en">Satybaldyev A.M., Karateev D.E. International practice of rheumatoid arthritis registries. Foreign registries. Modern Rheumatology J. 2014; 8(1): 83–84 DOI: 10.14412/1996-7012-2014-1-83-84 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Radner H., Dixon W., Hyrich K., Askling J. Consistency and utility of data items across European rheumatoid arthritis clinical cohort and registers. Arthritis Care Res. 2015 Apr 17. DOI: 10/1002/acr.22602.</mixed-citation><mixed-citation xml:lang="en">Radner H., Dixon W., Hyrich K., Askling J. Consistency and utility of data items across European rheumatoid arthritis clinical cohort and registers. Arthritis Care Res. 2015 Apr 17. DOI: 10/1002/acr.22602.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Smolen J.S., Breedveld F.C., Burmester G.R. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 2015; May 12. PII: annrheumdis-2015-207524. DOI: 10.1136/annrheumdis-2015-207524.</mixed-citation><mixed-citation xml:lang="en">Smolen J.S., Breedveld F.C., Burmester G.R. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 2015; May 12. PII: annrheumdis-2015-207524. DOI: 10.1136/annrheumdis-2015-207524.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Отс О.Н., Агкацев Т.В., Перельман М.И. Хирургическое лечение туберкулеза легких при устойчивости микобактерий к химиопрепаратам. Сеченовский вестник. 2012; 2(8): 15–23.</mixed-citation><mixed-citation xml:lang="en">Ots O.N., Agkatsev T.V., Perel’man M.I. Surgical treatment for pulmonary tuberculosis with mycobacterium resistance to drugs. Sechenovskiy Vestnik. 2012; 2(8): 15–23 (in Russian).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
